OLMA Olema Pharmaceuticals, Inc.
7.940USD+0.25%Mkt Cap: 694.73M $P/E: —1d ago
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results Olema Pharmaceuticals (NASDAQ:OLMA) shares fell 15. 1% in pre-market trading to $8. | ||
Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks from the technology. | ||